Real-world evaluation of compliance and preference in Alzheimer’s disease treatment
Ming-Chyi Pai,1,2 Hany Aref,3 Nazem Bassil,4 Nagaendran Kandiah,5 Jae-Hong Lee,6 AV Srinivasan,7 Shelley diTommaso,8 Ozgur Yuksel81Division of Behavioral Neurology, Department of Neurology, 2Alzheimer’s Disease Research Center, National Cheng Kung University Hospital, College of Medicine,...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e115521c071045b88a727d093dcf45db |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e115521c071045b88a727d093dcf45db |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e115521c071045b88a727d093dcf45db2021-12-02T07:04:34ZReal-world evaluation of compliance and preference in Alzheimer’s disease treatment1178-1998https://doaj.org/article/e115521c071045b88a727d093dcf45db2015-11-01T00:00:00Zhttps://www.dovepress.com/real-world-evaluation-of-compliance-and-preference-in-alzheimerrsquos--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Ming-Chyi Pai,1,2 Hany Aref,3 Nazem Bassil,4 Nagaendran Kandiah,5 Jae-Hong Lee,6 AV Srinivasan,7 Shelley diTommaso,8 Ozgur Yuksel81Division of Behavioral Neurology, Department of Neurology, 2Alzheimer’s Disease Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan; 3Department of Neurology, Ain Shams University, Cairo, Egypt; 4Saint Georges Hospital Medical Center, Balamand University, Beirut, Lebanon; 5Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore; 6Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea; 7The Tamil Nadu Dr MGR Medical University, Chennai, Tamil Nadu, India; 8Novartis Pharma AG, Postfach, Basel, SwitzerlandPurpose: Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer’s disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer’s disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer’s disease.Patients and methods: RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer’s disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24.Results: A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers’ preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transdermal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001).Conclusion: Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.Keywords: rivastigmine, Alzheimer’s disease, cholinesterase inhibitors, patient compliance, observational study, transdermal patchPai MCAref HBassil NKandiah NLee JHSrinivasan AVdiTommaso SYuksel ODove Medical PressarticleRivastigmineAlzheimer's diseasecholinesterase inhibitorspatient complianceobservational studyclinical trialsGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 10, Pp 1779-1788 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Rivastigmine Alzheimer's disease cholinesterase inhibitors patient compliance observational study clinical trials Geriatrics RC952-954.6 |
| spellingShingle |
Rivastigmine Alzheimer's disease cholinesterase inhibitors patient compliance observational study clinical trials Geriatrics RC952-954.6 Pai MC Aref H Bassil N Kandiah N Lee JH Srinivasan AV diTommaso S Yuksel O Real-world evaluation of compliance and preference in Alzheimer’s disease treatment |
| description |
Ming-Chyi Pai,1,2 Hany Aref,3 Nazem Bassil,4 Nagaendran Kandiah,5 Jae-Hong Lee,6 AV Srinivasan,7 Shelley diTommaso,8 Ozgur Yuksel81Division of Behavioral Neurology, Department of Neurology, 2Alzheimer’s Disease Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan; 3Department of Neurology, Ain Shams University, Cairo, Egypt; 4Saint Georges Hospital Medical Center, Balamand University, Beirut, Lebanon; 5Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore; 6Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea; 7The Tamil Nadu Dr MGR Medical University, Chennai, Tamil Nadu, India; 8Novartis Pharma AG, Postfach, Basel, SwitzerlandPurpose: Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer’s disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer’s disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer’s disease.Patients and methods: RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer’s disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24.Results: A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers’ preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transdermal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001).Conclusion: Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.Keywords: rivastigmine, Alzheimer’s disease, cholinesterase inhibitors, patient compliance, observational study, transdermal patch |
| format |
article |
| author |
Pai MC Aref H Bassil N Kandiah N Lee JH Srinivasan AV diTommaso S Yuksel O |
| author_facet |
Pai MC Aref H Bassil N Kandiah N Lee JH Srinivasan AV diTommaso S Yuksel O |
| author_sort |
Pai MC |
| title |
Real-world evaluation of compliance and preference in Alzheimer’s disease treatment |
| title_short |
Real-world evaluation of compliance and preference in Alzheimer’s disease treatment |
| title_full |
Real-world evaluation of compliance and preference in Alzheimer’s disease treatment |
| title_fullStr |
Real-world evaluation of compliance and preference in Alzheimer’s disease treatment |
| title_full_unstemmed |
Real-world evaluation of compliance and preference in Alzheimer’s disease treatment |
| title_sort |
real-world evaluation of compliance and preference in alzheimer’s disease treatment |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/e115521c071045b88a727d093dcf45db |
| work_keys_str_mv |
AT paimc realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment AT arefh realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment AT bassiln realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment AT kandiahn realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment AT leejh realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment AT srinivasanav realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment AT ditommasos realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment AT yukselo realworldevaluationofcomplianceandpreferenceinalzheimerrsquosdiseasetreatment |
| _version_ |
1718399666595299328 |